ICPA Icpamox-CV 625mg Tablets

ICPA ICPAMOX-CV 625mg Tablets combine the antibiotic power of Amoxycillin 500mg with Clavulanic acid 125mg to provide a broad-spectrum treatment against bacterial infections. This formulation is particularly effective against pathogens in the oral cavity and other body parts, thanks to the beta-lactamase inhibitory action of Clavulanic acid, which extends Amoxycillin’s effectiveness to a wider range of organisms, including those resistant to other beta-lactam antibiotics. ICPAMOX-CV 625 is indicated for use in treating acute periapical abscesses, reducing post-operative pain before endodontic treatments, and preventing post-operative infections and bacteremia following tooth extractions and other oral surgeries. It is also effective in preventing infections and dry socket post-wisdom tooth surgeries, treating pericoronitis, peri-implantitis, and periodontitis as an adjunct to scaling and root planing, as well as periodontal surgeries and abscesses. Additionally, it is used in the treatment of facial cellulitis. Common side effects may include diarrhea, stomach upset, nausea, vomiting, and mild skin rash.

Indications:

• Acute periapical abscess
• Pre-endodontic treatment for pain reduction
• Post-tooth extraction infection prevention
• Oral surgeries to reduce post-operative infection and bacteremia
• Pre-wisdom tooth surgery to prevent infection and dry socket
• Pericoronitis and peri-implantitis
• Adjunct to scaling and root planing in periodontitis
• Periodontal surgeries and abscesses
• Facial cellulitis